AzTrials
AzTrials

Small Bowel DiseaseNCT05004207

Study of Oro-cecal Transit Time in Healthy Subjects Using Scintigraphy and Lactulose Hydrogen Breath Test.

An observational study of Small Bowel Disease and Motility Disorder, run by Asian Institute of Gastroenterology, India at 1 site in India.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Radionuclide scintigraphy is the gold standard technique to interpret OCTT but there is no normative data available for its interpretation in Indian population. Previous studies to determine OCTT have all been done with LHBT, which has many limitations. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
99mTc Scintigraphy
How many people
50 participants
Where
1 siteIndia
Study dates
1 Jul 2021to 31 Jan 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Healthy individual > 18 years of age with no comorbidities

Who may be able to join

  • Healthy individual > 18 years of age with no comorbidities

Who cannot join

  • Thoracic or digestive foregut surgery,
  • Alcohol consumption >40 g/day,
  • Use of medications that alter intragastric acidity or oesophageal motility
  • History of diabetes mellitus, thyroid disorder
  • Neurological disorders
  • Chronic gastrointestinal disease
  • Any subject with upper GI symptoms like pain, burning, belching, bloating, dysphagia \& aerophagia

Trial locations and contacts

1 site in 1 country.

Neeraj Singla, MBBS, MD, DM contact

7888619216 ext. 91

dr.neerajsingla@gmail.com

Aniruddha P Singh, MBBS, MD, DM contact

9004093248 ext. 91

draniruddhapratapsingh@gmail.com

India1 site, 1 recruiting
  • AIG Hospitals

    Hyderabad, Telangana, 500032

    Aniruddha P Singh, MBBS,MD,DM, 09004093248, draniruddhapratapsingh@gmail.com

    Neeraj Singla, MBBS,MD,DM, 07888619216, dr.neerajsingla@gmail.com

    Recruiting

Other trials in India

About this study

Official title: Oro-cecal Transit Time in Healthy Indian Subjects Using Scintigraphy and Its Correlation With Lactulose Hydrogen Breath Test- A Pilot Study

Radionuclide scintigraphy is the gold standard technique to interpret OCTT but there is no normative data available for its interpretation in Indian population. Previous studies to determine OCTT have all been done with LHBT, which has many limitations. Besides there are few small comparative studies between scintigraphy and LHBT, that too not in Indian population. The aim of this study is to validate LHBT to measure OCTT compared with scintigraphy and to standardize the normal OCTT in healthy individuals

Read the detailed description
  1. INTRODUCTION Oro-caecal transit time (OCTT) can be defined as time taken for the meal to reach from oral cavity to caecum and how long it takes for food to pass through small intestines. It's important because it influences how efficiently nutrients are absorbed from food and influences fermentation associated with healthy gut flora. Short transit time may be due to inflammation caused by intestinal infection, food allergies, or by absence of healthy intestinal flora. Long transit time is usually due to eating too much refined and processed foods, low thyroid, dehydration, lack of dietary fibre, serotonin deficiency and insufficient salt intake Several factors affect the oro-caecal transit time such as: physiological (age, sex, menstrual cycle), usage of stimulants (coffee, alcohol, cigarette smoking), as well as pathological conditions. Patients can have gastrointestinal symptoms, which may be secondary to small intestinal dysmotility which can be achieved by interpretation of oro- caecal transit time. Thus measurement of OCTT helps in various GI diseases eg. chronic constipation, chronic diarrhoea, Dyspepsia, Irritable bowel syndrome, chronic idiopathic intestinal pseudo-obstruction or functional recto-sigmoid obstruction, scleroderma, celiac disease \& Malabsorption syndrome. Two techniques are available to assess oro-cecal transit time, Lactulose hydrogen breath test and Radionuclide scintigraphy, where latter is the gold standard technique to interpret OCTT.
  2. RATIONALE Radionuclide scintigraphy is the gold standard technique to interpret OCTT but there is no normative data available for interpretation of OCTT in Indian population. Previous studies to determine OCTT have all been done with LHBT, which has many limitations. Besides there are few small comparative studies between scintigraphy and LHBT, that too not in Indian population. Interpretation of OCTT helps in assessment of various GI disorders which may be secondary to small intestinal dysmotility having gastrointestinal symptoms.
  3. STUDY POPULATION- 50 healthy asymptomatic subjects
  4. DESIGN AND DURATION OF THE STUDY- It will be a pilot study. The study duration will be till completion of data collection for 50 subjects.
  5. METHODOLOGY- 5a. SUBJECT RECRUITMENT - Healthy volunteers

5b. RANDOMIZATION AND BLINDING- N/A

5c. STUDY METHODS- This observational study will be conducted among 50 patients of both sexes after obtaining ethical clearance from institutional human ethical committee. Study participants will be of the age more than 18 years. Exclusion criteria will consist of thoracic or digestive foregut surgery, alcohol consumption >40 g/day, use of medications that alter intragastric acidity or esophageal motility, as well as history of diabetes mellitus, thyroid disorder, neurological disorders or other chronic gastrointestinal disease.

5d. STUDY PROCEDURE- Subjects will be advised to stop any medications that affect GI motility 2 days prior to testing and avoid strenuous exercise and cigarette smoking on the day of test. After fasting for at least 8 to 12 hours, standardised meal - 3 idli plus curd mixed with 18.5-37 Minimum Base Quantity (MBq) (0.5-1 mCi) of 99mTc-sulfur colloid radiolabelled test meal will be administered as quickly as possible, optimally within 10 min. Imaging will be obtained with Siemens Symbia E dual head scanner in a format of at least 128 x 128 pixels using a general-purpose collimator or a low energy high-resolution collimator The photopeak settings are 20% at the 140-keV (kiloelectron volt) peak for 99mTc. Anterior and posterior planar images (or a single left anterior oblique image) with the distal oesophagus, stomach, and proximal small bowel in the field of view will be obtained for 1 min immediately after ingestion of the test meal and Repeated images will be obtained in the same projections with 2 min static images at hourly intervals up to 6 h and 24 h, as was used for the initial images.

Next day after at least 12 hours of fasting with no strenuous exercise and cigarette smoking on the day of test, with no antibiotics 4 weeks prior to testing and no prokinetic drug or laxatives 2 weeks prior to testing. Following administration of test substrate (Lactulose 10 grams) with one cup of water, breath samples will be analysed for hydrogen every 15 minutes for 1 hour followed by every ½ hour for next 2 hour with LACTOFEN 2 device.

5e. METHODS OF ASSESSMENT-.The analysis process will consist of:

  1. Interpretation of oro-caecal transit time with scintigraphy i.e by the percentage accumulation of 99mTc in the caecum
  2. Interpretation of oro-caecal transit time with LHBT i.e the time interval between ingestion of lactulose and rise in breath hydrogen 20 ppm above basal
  3. Co-relation of oro-caecal time between scintigraphy and LHBT
  4. Sample Size Calculaion- It will be a pilot study. The study duration will be till completion of data collection for 50 subjects.
  5. Statistical Analysis- Data will be expressed as median and percentile values (5th, 25th, 75th and 95th percentiles). Depending on normality of distribution, we will use either paired Student's t-test or Mann-Whitney U test for paired comparison. Likewise, we will use one way analysis of variance with Tukey test or Kruskal-Wallis, followed by Dunn's test as appropriate. Upper limit of normal will be defined as the 95th percentile of normal values. P≤0.05 will be considered statistically significant.
  6. ETHICAL JUSTIFICATION OF THE STUDY - Both the procedure being done in this study are considered safe and not associated with any major adverse event. But there is very minimal risk of radiation exposure in radionuclide scintigraphy study, which is less than exposure to a chest X ray.There is no normative data available for interpretation of OCTT in Indian subjects using nuclear scintigraphy. The commonly used test for measurement of OCTT, i.e LHBT has also not been validated in Indian subjects as compared to the scintigraphy. This study will help us give a reference value for OCTT, which could be used for defining altered small bowel transit time.
Being tested
99mTc Scintigraphy
Keywords
Small bowel disease, Orocaecal transit time, nuclear scintigraphy, lactulose hydrogen breath test
Medical subject headings
Irritable Bowel Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 99mTc ScintigraphyDiagnostic test

    Also called Lactulose Hydrogen Breath test

    After fasting for at least 8 to 12 hours, standardized meal mixed with 99mTc-sulfur colloid radiolabeled test will be administered as quickly as possible, optimally within 10 min. Imaging will be obtained with Siemens SYMBIA E dual head (SPECT) scanner in a format of at least 128 x 128 pixels. Anterior and posterior planar images (or a single left anterior oblique image) with the distal esophagus, stomach, and proximal small bowel in the field of view will be obtained for 1 min immediately after ingestion of the test meal and repeated images will be obtained in the same projections with 2 min static images at hourly intervals up to 6 h and at 24 hours as was used for the initial images.

    Next day LHBT will be performed after at least 12 hours of fasting. Following administration of test substrate (Lactulose 10 grams) with one cup of water, breath samples will be analyzed for hydrogen every 15 minutes for 1 hour followed by every half hour for next 2 hour with LACTOFEN 2 device.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Oro-caecal transit time (OCTT) using lactulose hydrogen breath test (LHBT) and scintigraphy study.

    LHBT is the commonly used test for OCTT, but it has fallacies, since it itself increase intestinal motility, so this study aims to validate LHBT with scintigraphy which is the gold standard test.

    Measured: six months

Secondary outcomes (1)
  1. Normative data for OCTT using nuclear scintigraphy in healthy indian population.

    There is no reference values for nuclear scintigraphy in healthy indian patients. The study will help generate data to give reference values for OCTT using scintigraphy.

    Measured: six months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Aug 2021
  2. Study start1 Jul 2021
  3. Primary completion31 Jan 2022 (estimated)
  4. Study completion31 Jan 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05004207
Sponsor's protocol ID
AIG/IEC-BH&R 15/06.2021-02
Status last verified
Aug 2021
First submitted
4 Aug 2021
Last updated
13 Aug 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: There is no plan to share individual participant data.

Publications

  • Miller MA, Parkman HP, Urbain JL, Brown KL, Donahue DJ, Knight LC, Maurer AH, Fisher RS. Comparison of scintigraphy and lactulose breath hydrogen test for assessment of orocecal transit: lactulose accelerates small bowel transit. Dig Dis Sci. 1997 Jan;42(1):10-8. doi: 10.1023/a:1018864400566.

    PubMed 9009110
  • Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011 Mar;60(3):334-40. doi: 10.1136/gut.2009.205476. Epub 2010 Nov 26.

    PubMed 21112950
  • Ning Y, Lou C, Huang Z, Chen D, Huang H, Chen L, Zhang B, Dai N, Zhao J, Zhen X. Clinical value of radionuclide small intestine transit time measurement combined with lactulose hydrogen breath test for the diagnosis of bacterial overgrowth in irritable bowel syndrome. Hell J Nucl Med. 2016 May-Aug;19(2):124-9. doi: 10.1967/s002449910365. Epub 2016 Jun 22.

    PubMed 27331205
  • Zhao J, Zheng X, Chu H, Zhao J, Cong Y, Fried M, Fox M, Dai N. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients. Neurogastroenterol Motil. 2014 Jun;26(6):794-802. doi: 10.1111/nmo.12331. Epub 2014 Mar 18.

    PubMed 24641100
  • Gilmore IT. Orocaecal transit time in health and disease. Gut. 1990 Mar;31(3):250-1. doi: 10.1136/gut.31.3.250. No abstract available.

    PubMed 2182399

Questions about this trial

What is this clinical trial studying?

An observational study of Small Bowel Disease and Motility Disorder, run by Asian Institute of Gastroenterology, India at 1 site in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 13 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Neeraj Singla, MBBS, MD, DM (7888619216 ext. 91, dr.neerajsingla@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Oro-caecal transit time (OCTT) using lactulose hydrogen breath test (LHBT) and scintigraphy study. (time frame: six months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05004207, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in